Gastric Balloon in İzmir

Obesity in İzmir: The Aegean Dimension of the National Picture

Türkiye has the highest obesity prevalence in the World Health Organization European Region. According to the national survey conducted by the Turkish Society of Endocrinology and Metabolism covering the years 2017-2022, the prevalence of obesity among type 2 diabetes patients increased significantly over 5 years (PMID 40582352). This picture is a critical part of the health agenda that İzmir, along with all major provinces, faces.

Across Türkiye, 20.2% of the adult population is obese (BMI ≥30), while 66.8% fall into the overweight or obese category (TÜİK 2022; WHO 2022). According to the WHO 2022 European Region report, Türkiye has the highest obesity prevalence in this region (32.1%; WHO 2022). Obesity is not only an individual health problem but also a societal priority that increases the risk of chronic disease and places a burden on the healthcare system. Because of its direct association with type 2 diabetes, hypertension, sleep apnea, and joint problems, weight management is positioned at the center of a holistic health approach.

GLP-1 receptor agonists became widespread during this period; however, according to a meta-analysis including 18 randomized controlled trials and 3,771 patients, an average regain of 5.63 kg is observed when medication use is discontinued (PMID 41399474). İzmir's healthcare infrastructure, together with the Ege and Dokuz Eylül University hospitals, private clinics across the city, and 15 Allurion authorized clinics, offers a comprehensive ecosystem for obesity management in the region.

Obesity is directly associated with chronic diseases such as type 2 diabetes, hypertension, cardiovascular diseases, and sleep apnea. In this context, weight management is regarded not merely as an aesthetic goal but as a fundamental component of long-term health management. İzmir's strong academic medical infrastructure provides an environment conducive to implementing evidence-based practices in this field.

Healthcare Infrastructure and Access in İzmir

İzmir is the healthcare hub of the Aegean, with its strong university hospital infrastructure, advanced private health sector, and regional transportation network. The Ege and Dokuz Eylül Universities form the academic backbone of the region in terms of clinical research and specialist training; the medical faculties of both universities conduct active clinical studies in the field of obesity and metabolic diseases.

Adnan Menderes Airport makes İzmir accessible through both domestic and international connections. The İZBAN rail system, with its route extending from Torbalı to Aliağa, connects the airport with the city center and district clinics. This ease of transportation makes same-day visits possible from surrounding provinces such as Manisa, Aydın, Denizli, and Muğla. The 15 Allurion authorized clinics in İzmir are located across different districts such as Bornova, Karşıyaka, Konak, and Bayraklı.

The Treatment Process in İzmir: Step by Step

Initial Assessment: At an authorized clinic in İzmir, the clinician evaluates your health history, weight management goals, and suitability for the Allurion Program. This consultation forms the basis for personalizing the program.

Balloon Placement (15 min): The capsule is swallowed with water. Under fluoroscopy guidance, the balloon that settles in the stomach is inflated. This procedure, which requires no endoscopy, anesthesia, or surgery, is completed in 15 minutes; the patient returns directly to daily life after the procedure.

4-Month Balloon Period: The balloon regulates stomach capacity; the smart scale and the Allurion mobile app allow the clinician to perform remote monitoring. Digital coaching supports lifestyle change throughout this process.

Balloon Excretion and Aftercare: At the end of the 4th month, the balloon spontaneously deflates and is excreted from the body. This is followed by a 2-month follow-up period, completing the total 6-month program. FDA PMA Class III approval was obtained on February 23, 2026 (P250023).

Evidence-Based Weight Management in İzmir

A systematic review and meta-analysis published in 2024 comprehensively demonstrated the short-term weight loss efficacy and safety profile of the Allurion swallowable balloon (PMID 39174862). This study covers publications from 2016 to 2024 and represents the most up-to-date synthesis of evidence regarding swallowable balloon technology.

The Allurion Program is not merely a balloon application. Over the 6-month digital coaching process, the smart scale, mobile app, and clinician monitoring are offered together. This integration supports lasting results by bringing the cycle of measurement, feedback, and behavior change into daily life.

The Allurion Program received PMA Class III approval from the U.S. Food and Drug Administration (FDA) on February 23, 2026 (P250023). The 15 authorized clinics in İzmir provide services grounded in this evidence base, with clinicians who have completed the training and certification process organized by Allurion.

Practical Information for Patients Coming to İzmir

From within İzmir: Thanks to the İZBAN rail system and urban public transportation, reaching central clinic locations from İzmir's various districts is easy. The clinics in Karşıyaka, Bornova, Konak, and Bayraklı are positioned close to different residential areas.

From outside İzmir: For patients arriving via Adnan Menderes Airport, reaching the city center is directly possible by İZBAN. Same-day visits can be planned from Manisa, Aydın, Denizli, Muğla, and other Aegean provinces via intercity bus connections. The İzmir Bus Terminal offers frequent road connections to much of the Aegean.

Placement of the Allurion balloon is completed in 15 minutes, and after the procedure the patient can return to all daily activities, including driving. This feature, which requires no additional accommodation, facilitates program access for individuals coming from outside İzmir. The follow-up process is conducted remotely via the smart scale and mobile app; frequent visits to the clinic are not required.